XMT-2056

Emiltatug ledadotin (Emi-Le) shows promising clinical activity in TNBC patients previously treated with topo-1 ADCs, with a 23% ORR in B7-H4 high tumors. Well-tolerated, with no Grade 4/5 TRAEs. Expansion cohort initiated for TNBC patients post topo-1 ADC treatment. 2025 milestones include continued enrollment and data presentation.

Mersana Therapeutics received FDA Fast Track designation for XMT-1660, targeting advanced breast cancer, including HER2 low/negative and TNBC, post topoisomerase-1 inhibitor ADC treatment. WHO approved 'Emi-Le' as XMT-1660's INN. The designation aims to expedite drug development for unmet medical needs, offering benefits like Accelerated Approval.

Mersana Therapeutics received a 'Moderate Buy' rating from analysts, with a $6.00 average target price. Citigroup rated it 'buy' at $5.00. Institutional investors increased stakes, owning 93.92% of the stock. The company reported ($0.09) EPS, beating estimates, with a 63.6% revenue increase. Mersana develops ADCs for cancer treatment.

Mersana Therapeutics received FDA Fast Track designation for XMT-1660, targeting advanced/metastatic triple-negative breast cancer. XMT-1660, a B7-H4-directed ADC, shows promise in preclinical studies, with a Phase 1 trial underway to assess its safety and efficacy in solid tumors, including breast, endometrial, and ovarian cancers.